Carlos López-Gómez obtained his PhD in 2013 in the Neuroimmunology and Multiple Sclerosis research group at IBIMA in Malaga under the direction of Dr. Laura Leyva and Dr. Óscar Fernández. He focused his research on the study of TRAIL and TRAIL receptor genes in susceptibility to multiple sclerosis and the response to IFN-beta therapy. During this period, he published three research articles as first author, as well as several articles as co-author, and he received one poster award. After his PhD, he moved to the United States for his postdoctoral training. There, he worked as a postdoctoral research scientist in Michio Hirano’s laboratory within the Department of Neurology at Columbia University in New York City. There, he studied TK2 deficiency, an autosomal recessive disorder affecting mitochondrial DNA and usually manifesting as a myopathy or encephalomyopathy. In March 2019, he moved back to Malaga to join the Eduardo García Fuentes Lab at IBIMA with a Juan de la Cierva-Incorporación grant. Here, he is currently studying genetic and environmental factors associated with Crohn's disease under a Miguel Servet contract (tenure track) at IBIMA.